+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Neuroprotection Market by Product (Apoptosis Inhibitors, Free Anti-Inflammatory Agents, Glutamate Antagonists), Treatment (Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury), Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 196 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4857892
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neuroprotection Market size was estimated at USD 14.76 billion in 2023, USD 16.20 billion in 2024, and is expected to grow at a CAGR of 9.86% to reach USD 28.52 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neuroprotection Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neuroprotection Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neuroprotection Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abcam PLC, AstraZeneca PLC, Astrocyte Pharmaceuticals Inc., Bayer AG, Biogen Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Neuren Pharmaceuticals, Novartis AG, Sangamo Therapeutics, Inc., and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Neuroprotection Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Apoptosis Inhibitors
    • Free Anti-Inflammatory Agents
    • Glutamate Antagonists
    • Metal Ion Chelators
    • Neurotrophic Factors
    • Radical Trapping Agents
    • Stimulants
  • Treatment
    • Alzheimer's Disease
    • Amyotrophic Lateral Sclerosis
    • Brain Injury
    • Huntington's Disease
    • Multiple Sclerosis
    • Neuropathies
    • Ocular Degeneration
    • Parkinson's Disease
  • Application
    • Prevention
    • Treatment
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Neuroprotection Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neuroprotection Market?
  3. What are the technology trends and regulatory frameworks in the Neuroprotection Market?
  4. What is the market share of the leading vendors in the Neuroprotection Market?
  5. Which modes and strategic moves are suitable for entering the Neuroprotection Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Neuroprotection Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidences of CNS diseases
5.1.1.2. Increased demand for target-specific drug treatment for neurodegenerative diseases
5.1.1.3. Increasing healthcare infrastructure and increasing economic stability
5.1.2. Restraints
5.1.2.1. Limited awareness in developing economies
5.1.3. Opportunities
5.1.3.1. New product launch, investment in R&D, and increasing drug discovery & product launch
5.1.3.2. Increasing use of neuroprotection in cosmetics
5.1.4. Challenges
5.1.4.1. High cost associated with neuro treatments
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Neuroprotection Market, by Product
6.1. Introduction
6.2. Apoptosis Inhibitors
6.3. Free Anti-Inflammatory Agents
6.4. Glutamate Antagonists
6.5. Metal Ion Chelators
6.6. Neurotrophic Factors
6.7. Radical Trapping Agents
6.8. Stimulants
7. Neuroprotection Market, by Treatment
7.1. Introduction
7.2. Alzheimer's Disease
7.3. Amyotrophic Lateral Sclerosis
7.4. Brain Injury
7.5. Huntington's Disease
7.6. Multiple Sclerosis
7.7. Neuropathies
7.8. Ocular Degeneration
7.9. Parkinson's Disease
8. Neuroprotection Market, by Application
8.1. Introduction
8.2. Prevention
8.3. Treatment
9. Americas Neuroprotection Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Neuroprotection Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Neuroprotection Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. Abcam PLC
13.1.3. AstraZeneca PLC
13.1.4. Astrocyte Pharmaceuticals Inc.
13.1.5. Bayer AG
13.1.6. Biogen Inc.
13.1.7. Daiichi Sankyo Company, Limited
13.1.8. Eisai Co., Ltd.
13.1.9. Eli Lilly and Company
13.1.10. F. Hoffmann-La Roche Ltd.
13.1.11. GlaxoSmithKline PLC
13.1.12. Neuren Pharmaceuticals
13.1.13. Novartis AG
13.1.14. Sangamo Therapeutics, Inc.
13.1.15. Teva Pharmaceutical Industries Ltd.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. NEUROPROTECTION MARKET RESEARCH PROCESS
FIGURE 2. NEUROPROTECTION MARKET SIZE, 2022 VS 2030
FIGURE 3. NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NEUROPROTECTION MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. NEUROPROTECTION MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. NEUROPROTECTION MARKET DYNAMICS
FIGURE 7. NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 8. NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
FIGURE 10. NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 12. NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 14. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 16. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 22. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. NEUROPROTECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. NEUROPROTECTION MARKET SIZE, BY APOPTOSIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. NEUROPROTECTION MARKET SIZE, BY FREE ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. NEUROPROTECTION MARKET SIZE, BY GLUTAMATE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. NEUROPROTECTION MARKET SIZE, BY METAL ION CHELATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. NEUROPROTECTION MARKET SIZE, BY RADICAL TRAPPING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. NEUROPROTECTION MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 14. NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. NEUROPROTECTION MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. NEUROPROTECTION MARKET SIZE, BY BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. NEUROPROTECTION MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. NEUROPROTECTION MARKET SIZE, BY NEUROPATHIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. NEUROPROTECTION MARKET SIZE, BY OCULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 23. NEUROPROTECTION MARKET SIZE, BY PREVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. NEUROPROTECTION MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. CANADA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 36. CANADA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 37. CANADA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. MEXICO NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 39. MEXICO NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. MEXICO NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. CHINA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 53. CHINA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. CHINA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. INDIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 56. INDIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. INDIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. INDONESIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 59. INDONESIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 60. INDONESIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. JAPAN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 62. JAPAN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. JAPAN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. MALAYSIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 65. MALAYSIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. MALAYSIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. SINGAPORE NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 71. SINGAPORE NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 72. SINGAPORE NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 74. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. TAIWAN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 77. TAIWAN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 78. TAIWAN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. THAILAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. THAILAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. THAILAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. VIETNAM NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 83. VIETNAM NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 84. VIETNAM NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. DENMARK NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 90. DENMARK NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. DENMARK NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. EGYPT NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 93. EGYPT NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 94. EGYPT NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. FINLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 96. FINLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. FINLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. FRANCE NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 99. FRANCE NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 100. FRANCE NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. GERMANY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 102. GERMANY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 103. GERMANY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. ISRAEL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 105. ISRAEL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 106. ISRAEL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. ITALY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 108. ITALY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 109. ITALY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 111. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 112. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. NIGERIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 114. NIGERIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 115. NIGERIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. NORWAY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 117. NORWAY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 118. NORWAY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. POLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 120. POLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 121. POLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. QATAR NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 123. QATAR NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 124. QATAR NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 132. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. SPAIN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 135. SPAIN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 136. SPAIN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. SWEDEN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 138. SWEDEN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 139. SWEDEN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 141. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 142. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. TURKEY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 144. TURKEY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 145. TURKEY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 153. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2022
TABLE 154. NEUROPROTECTION MARKET LICENSE & PRICING

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Abcam PLC
  • AstraZeneca PLC
  • Astrocyte Pharmaceuticals Inc.
  • Bayer AG
  • Biogen Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Neuren Pharmaceuticals
  • Novartis AG
  • Sangamo Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 16.2 Billion
Forecasted Market Value ( USD ) by 2030 $ 28.52 Billion
Compound Annual Growth Rate9.8%
Regions CoveredGlobal

Related Topics

Related Reports

Neuroprotection Therapeutics - Global Strategic Business Report - Product Image

Neuroprotection Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Neuroprotection Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application - Product Image

Neuroprotection Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application

  • Report
  • 90 Pages
  • Global
From
Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172 - Product Image

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172

  • Book
  • Global
Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-morbidity Factors Part A. International Review of Neurobiology Volume 171 - Product Image

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-morbidity Factors Part A. International Review of Neurobiology Volume 171

  • Book
  • Global
Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis. Edition No. 1 - Product Image

Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis. Edition No. 1

  • Book
  • 404 Pages

About the Neuroprotection Market

The Neuroprotection market within the context of Neurology Devices is focused on the development of products that protect the brain from damage caused by stroke, traumatic brain injury, and other neurological disorders. These products are designed to reduce the risk of long-term neurological damage and improve patient outcomes. Neuroprotection products include drugs, medical devices, and other therapies that can be used to reduce the risk of neurological damage. These products are used to reduce the risk of stroke, traumatic brain injury, and other neurological disorders. The Neuroprotection market is a rapidly growing segment of the Neurology Devices market, with a focus on improving patient outcomes and reducing the risk of long-term neurological damage. Companies in this market include Medtronic, Abbott, Boston Scientific, Stryker, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.